Skip to content

RandomizEd comparison of PRogrESsion of atherosclerotic plaquEs aNd calcification of coronary artery in Atrial Fibrillation Patients treated with edoxaban versus warfarin (The REPRESENT-AF trial).

RandomizEd comparison of PRogrESsion of atherosclerotic plaquEs aNd calcification of coronary artery in Atrial Fibrillation Patients treated with edoxaban versus warfarin (The REPRESENT-AF trial).

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004133
Enrollment
150
Registered
2019-07-11
Start date
2019-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hallym University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.NVAF with CHA2DS2-VASc score =1 2.Coronary artery disease the coronary artery is observed to have at least 20% arteriosclerotic stenosis in Coronary computed tomography angiography 3.Patients who have not previously taken oral anticoagulants 4.Age greater than or equal to 19 years 5.Willing and able to provide informed consent

Exclusion criteria

Exclusion criteria: 1.Unstable angina 2.Patients who have undergone a coronary stent procedure within the previous 12 months 3.Patients who have diagnosed with stroke within the previous 3 months 4.Moderate to severe mitral stenosis 5.Hypertrophic cardiomyopathy 6.Renal insufficiency (calculated CrCl <30 mL/min) 7.Patients who cannot take oral anticoagulants 8.Platelet count of <100 000/mm3 or Hgb <10 g/dL 9.GI bleeding event in the previous 6 months 10.Pregnancy

Design outcomes

Primary

MeasureTime frame
changes in volume and character of the plaque of coronary arteries;Incidence of major bleeding

Secondary

MeasureTime frame
major cardiovascular events

Countries

Korea, Republic of

Contacts

Public ContactHong Euy Lim

Hallym University Medical Center

hongeuy1046@gmail.com+82-31-380-3889

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026